Inspire Medical Systems, Inc. (NYSE:INSP) Given Consensus Rating of “Hold” by Analysts

Inspire Medical Systems, Inc. (NYSE:INSP) has earned a consensus rating of “Hold” from the twenty ratings firms that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $81.8421.

A number of equities analysts have commented on the stock. Wells Fargo & Company dropped their price objective on shares of Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 5th. Oppenheimer reissued a “market perform” rating on shares of Inspire Medical Systems in a research note on Monday, June 15th. Truist Financial dropped their price objective on shares of Inspire Medical Systems from $64.00 to $50.00 and set a “hold” rating for the company in a research note on Tuesday, May 5th. Weiss Ratings cut shares of Inspire Medical Systems from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 6th. Finally, Bank of America cut shares of Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 price objective for the company. in a research note on Friday, May 22nd.

Institutional Investors Weigh In On Inspire Medical Systems

Several institutional investors have recently made changes to their positions in INSP. Royal Bank of Canada lifted its holdings in shares of Inspire Medical Systems by 16.0% in the 1st quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock worth $5,220,000 after acquiring an additional 4,528 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in Inspire Medical Systems during the 1st quarter valued at about $524,000. Goldman Sachs Group Inc. lifted its holdings in Inspire Medical Systems by 57.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock valued at $8,190,000 after buying an additional 18,857 shares in the last quarter. Marshall Wace LLP lifted its holdings in Inspire Medical Systems by 3.8% during the 2nd quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock valued at $2,064,000 after buying an additional 577 shares in the last quarter. Finally, Jump Financial LLC bought a new stake in Inspire Medical Systems during the 2nd quarter valued at about $931,000. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Stock Down 2.5%

Shares of NYSE:INSP opened at $41.55 on Tuesday. Inspire Medical Systems has a 52 week low of $38.91 and a 52 week high of $147.03. The stock has a market capitalization of $1.20 billion, a P/E ratio of 9.25, a PEG ratio of 4.31 and a beta of 0.73. The firm has a fifty day simple moving average of $46.49 and a two-hundred day simple moving average of $67.80.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings data on Monday, May 4th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The business had revenue of $204.58 million during the quarter, compared to analysts’ expectations of $200.04 million. During the same period last year, the company posted $0.10 EPS. The business’s revenue was up 1.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, analysts expect that Inspire Medical Systems will post 0.93 earnings per share for the current year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.